Martin B. Gill, PhD
Director, Head of In Vitro Pharmacology at Neuropore Therapies, Inc.
Location: San Diego, California, United States
Martin Gill, PhD, received his doctorate in neuroscience from the University of Texas-Medical Branch investigating cell death during neurodegeneration. He conducted postdoctoral work at Northwestern University, Feinberg School of Medicine, in Illinois, studying glutamate receptors -- proteins on the surface of brain cells that participate in cell-to-cell communication -- in addition to novel, marine-based molecules that could change the function of brain cells. In 2009, Dr. Gill joined Eli Lilly and Company as a member of the Neuroscience Discovery team supporting target identification/validation and lead optimization efforts. In 2011, he joined the Genetically-Defined Disease division at Bristol-Myers Squibb, where he managed a senior scientific team focused on in vitro/in vivo assay development to support portfolio program progression. In addition, he served as biology co-chair for internal small-molecule and antisense programs, as well as managed the biological evaluation of in-licensing asset opportunities. Dr. Gill joined the Neuropore Therapies team in 2016. At Neuropore Therapies, he manages the in vitro discovery efforts to identify, validate and optimize novel small-molecule therapeutics for inflammation-/autophagy-based targets.